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Abstract
Aims/hypothesis Hypoxia in the initial days after islet
transplantation leads to considerable loss of islet mass and
contributes to disappointing outcomes in the clinical setting.
The aim of the present study was to investigate whether
co-transplantation of human non-endothelial bone marrow-
derived multipotent adult progenitor cells (MAPCs), which
are non-immunogenic and can secrete angiogenic growth
factors during the initial days after implantation, could
improve islet engraftment and survival.
Methods Islets (150) were co-transplanted, with or without
human MAPCs (2.5×105) as separate or composite pellets,
under the kidney capsule of syngeneic alloxan-induced
diabetic C57BL/6 mice. Blood glucose levels were frequently
monitored and IPGTTs were carried out. Grafts and serum
were harvested at 2 and 5 weeks after transplantation to assess
outcome.
Results Human MAPCs produced high amounts of angioge-
nic growth factors, including vascular endothelial growth
factor, in vitro and in vivo, as demonstrated by the induction
of neo-angiogenesis in the chorioallantoic membrane assay.
Islet–human MAPC co-transplantation as a composite pellet
significantly improved the outcome of islet transplantation as
measured by the initial glycaemic control, diabetes reversal
rate, glucose tolerance and serum C-peptide concentration
compared with the outcome following transplantation of islets
alone. Histologically, a higher blood vessel area and density in
addition to a higher vessel/islet ratio were detected in
recipients of islet–human MAPC composites.
Conclusions/interpretation The present data suggest that
co-transplantation of mouse pancreatic islets with human
MAPCs, which secrete high amounts of angiogenic growth
factors, enhance islet graft revascularisation and subsequently
improve islet graft function.
Keywords Islet . Revascularisation . Stem cells . Type 1
diabetes
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Introduction
To date, insulin therapy is considered the gold standard for the
treatment of type 1 diabetes. Nevertheless limitations persist,
such as frequent episodes of hypoglycaemia, and develop-
ment chronic micro- and macrovascular complications [1, 2].
Islet transplantation offers an alternative treatment for patients
with type 1 diabetes, especially for those with hypoglycaemic
unawareness following insulin administration. Despite the
improved outcome of islet transplantation over the last few
years, drawbacks remain, such as a limited supply of
cadaveric donors, the necessity of several donors for a single
transplantation and (immediate) graft failure through
metabolic pressure, continued autoimmunity, alloimmunity,
high concentrations of immunosuppressive drugs and
oxidative stress caused by hypoxia or due to cytokine
exposure [3]. Rapid revascularisation of the islets seems
crucial to avoid beta cell stress by hypoxia and inflammatory
cytokines. Several studies aiming to improve engraftment
with cell therapy are currently ongoing (Clinical Trial.gov
registration no. NCT00646724, NCT02384018).
Mesenchymal stem cells (MSCs, 30–35 μm in diameter),
the major stem cells used for cell therapy, are self-renewing
cells that can be isolated from the bone marrow and possibly
also from many (if not all) tissues; for over 10 years MSCs
have shown benefits in the treatment of several clinical
diseases, mainly tissue injury and immune disorders [4–6].
When co-transplanted with islets, MSCs improve islet
transplantation outcome in preclinical animal models through
immunomodulation, increasing islet revascularisation and/or
preserving islet morphology [7–10]. Despite the progress
made in the understanding of MSC biology, there is little
knowledge on the nature of their local microenvironment
(probably hypoxic) and their functions in vivo. Moreover,
long population doubling time, early senescence and DNA
damage during in vitro expansion, as well as poor engraftment
after transplantation, are considered to be among the key dis-
advantages ofMSC therapy [11]. Furthermore, with long-term
culture expansion, MSCs can become karyotypical abnormal,
potentially posing a risk of tumour formation.
Multipotent adult progenitor cells (MAPCs, 15–20 μm in
diameter) are adult stem cells isolated from postnatal bone
marrow, muscle or brain from rodents and humans [12, 13].
These non-haematopoietic, non-endothelial stem cells most
probably use similar immunosuppressive and angiogenic
mechanisms to those used by MSCs, while displaying unique
features (e.g. secretome, transcriptome and microRNA
profiles) distinct from those of most adult stem cells
[14–17]. Interestingly, MAPCs have been shown to promote
tissue repair and healing and induce neo-angiogenesis,
possibly by delivering angiogenic growth factors that activate
or recruit endogenous vascular cells and that seem to be
specifically tailored to the immediate needs of the injured
tissue [18–21]. In vivo, these cells are short-lived as they
experience only a minimally prolonged residence time.
Moreover, in contrast to other cell types, MAPCs can be
expanded in the long term (for > 80 population doublings)
without genetic instability and can be administered without
tissue matching, making them into an optimal stem cell
product for routine clinical use (MultiStem; Athersys,
Cleveland, OH, USA). Therefore, we aimed in this study to
assess the therapeutic efficacy of co-transplantation of
undifferentiated human MAPCs with mouse islets as separate
or composite pellets in a syngeneic marginal mass islet
transplantation model.
Methods
Animals C57BL/6 mice (purchased from Charles River,
L’Arbresle, France) were used as islet donors and transplant
recipients in all procedures. The mice were handled in
accordance with the Guide for the Care and Use of Laboratory
Animals, 18th edition (2011) as well as Katholieke Universiteit
Leuven (KULEUVEN, Leuven, Belgium) Animal Care and Use
Guidelines.
Preparation and characterisation of human MAPCs
Human MAPCs (n= 2) used in this study were isolated
by ReGenesys BVBA (Athersys affiliate; Heverlee,
Belgium) from the bone marrow of a 30-year-old female
and a 45-year-old male volunteer, with informed consent
and ethical approval. Isolation and culture of the cells was
carried out as outlined in electronic supplementary material
(ESM) Methods [22].
Phenotypic analysis of the human MAPCs was performed
using fluorochrome-conjugated antibodies recognising cluster
of differentiation (CD) 3, CD31, CD34, CD40, CD44, CD86,
CD105, fetal liver kinase 1 (Flk1), HLA-ABC and HLA-DR
(ebioscience, San Diego, CA, USA). Acquisition was done by
using a Gallios multicolour flow cytometer (Beckman
Coulter, Suarlée, Belgium). For analysis of the samples,
FlowJo version 10.1 (Tree Star, Ashland, OR, USA) software
was used.
Cell-free supernatant fractions were assayed for a
pro-inflammatory, cytokine, chemokine, angiogenesis and
vascular inflammation panel (see ESMMethods) bymultiplex
electrochemiluminescence (Meso Scale Discovery, Rockville,
MD, USA) as per manufacturer’s protocol.
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The angiogenic potential of human MAPCs was
examined in the chick chorioallantoic membrane
(CAM) as described [23].
Marginal mass syngeneic islet transplantation diabetes
model To induce diabetes in recipients, a single intravenous
injection of alloxan (90 mg/kg body weight; Sigma-Aldrich,
St. Louis, MO, USA) was administered to 8- to 10-week-old
male C57BL/6 mice, and animals were considered to be dia-
betic after two consecutive non-fasting tail-vein blood glucose
concentrations of≥11.1 mmol/l, measured by an AccuChek
Glucometer (Roche Diagnostics, Vilvoorde, Belgium). Before
transplantation, islets from 2- to 3-week-old male C57BL/6
mice were isolated by collagenase digestion, washed, counted
and sometimes mixed with human MAPCs (see ESM
Methods) [24]. For more details see ESMMethods. On weeks
2 and 5 after transplantation, graft-bearing kidneys were
removed and fixed in 4% formaldehyde followed by paraffin
embedding or were used for RNA isolation.
Physiological studiesGlucose tolerance tests were performed
after mice had been fasted for 16 h. Mice were injected
intraperitoneally with D-glucose (2 g/kg body weight), and
blood glucose levels were measured at the indicated times.
For serum insulin and C-peptide determination, blood was
collected from the saphenous vein. Serum was isolated by
centrifugation and levels of pancreatic hormones were
determined by ultrasensitive ELISA kits (Mercodia,
Uppsala, Sweden; Merck Millipore, Billerica, MA, USA).
Morphometry and immunohistochemistry Graft-bearing
kidneys were embedded in paraffin and 6 μm sections were
obtained from the total graft area. Stainings for insulin (guinea
pig, no. A0564; DakoBelgium, Heverlee, Belgium), glucagon
(mouse, no. G2654; Sigma, St Louis, MO, USA), somatosta-
tin (rat, no. ab30788; Abcam, Cambridge, UK), endomucin
(rat, no. sc-65495; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and α-smooth muscle actin (α-SMA) (goat, no.
EB06450; Everest Biotech, Upper Heyford, UK) were used
to evaluate beta cell mass and blood vessel density with the aid
of a Ventana Ultra staining platform (Roche). The endomucin
and α-SMA antibodies are recommended for detection of
endomucin or α-SMA, respectively, of mouse and not human
origin. All antibodies were validated in previous studies.
For quantification of beta cell and blood vessel volume, all
images were captured using a Nikon Eclipse TE2000-E
microscope using a×40 magnification objective and the large
image-capture feature so that the entire graft area of each
section could be pictured at once. Insulin-, glucagon- and
somatostatin-positive areas, as well as endomucin-positive
areas, within the endocrine compartment of the islet graft were
measured semi-automatically by open-source image proces-
sing package based on ImageJ, Fiji version software (National
Institutes of Health, Bethesda, MD, USA) on approximately
15% (i.e. every fifth section) of the total graft as described
[25]. The vessel/beta cell ratio was calculated as (blood vessel
area/insulin-positive area) × 100%. Vessel density was
calculated as the number of intra-islet vessels per mm2.
Quantitative PCR Islet graft RNAwas isolated as described
[26]. Primer and probe sequences are listed in ESM Table 1.
Results are expressed as 2−ΔΔCt (see ESM Methods).
Statistics Statistics were calculated with Prism software 5.0
(GraphPad Software, San Diego, CA, USA). The χ2 test was
applied to identify the significance of the difference between
diabetes reversal rates when comparing different groups. All
numerical values were presented as the mean±SEM, unless
otherwise indicated. Significance was determined using the
Mann–Whitney U test or Kruskal–Wallis test, and a value of
p<0.05 was considered significant.
Results
Human MAPCs secrete angiogenic growth factors and
have neo-angiogenic potential in the in vivo CAM assay
Human MAPCs expressed low levels of HLA-ABC (<25%)
and they did not express HLA-DR, CD40, CD86, CD3, Flk1
(also known as vascular endothelial growth factor [VEGF]
receptor 2 or kinase insert domain receptor [KDR]), CD31
(also known as platelet endothelial cell adhesion molecule
[PECAM]-1) or CD34 (<1%), which are typical cell surface
markers for MHC class II and co-stimulation molecules, T
cells and endothelial cells, respectively (Fig. 1a). Human
MAPCs were positive for CD44 and CD105 (>95%) [27].
Their surface marker signature defines a unique phenotype
that distinguishes them from any other known class of stem
cells [27].
The culture supernatant fraction of human MAPCs was
analysed with human biomarker 40-Plex kit containing a
pro-inflammatory panel, cytokine panel, chemokine panel,
angiogenesis panel and vascular inflammation panel
(Fig. 1b). The cells produced numerous angiogenic growth
factors, including VEGF (VEGF-A, -C and -D), placental
growth factor (PlGF), soluble fms-like tyrosine kinase-1
(sFlt-1), basic fibroblast growth factor (bFGF) and IL8. On
the other hand, the cells secreted negligible amounts of
various cytokines (IFN-γ, IL1α, IL1β, IL2, IL4, IL5, IL6,
IL7, IL10, IL12p70, IL12/IL23p40, IL13, IL15, IL16,
IL17A, TNF-α and TNF-β) and chemokines (eotaxin,
eotaxin-3, IFN-γ-induced protein 10 [IP-10], monocyte
chemoattractant protein [MCP]-1, MCP-4, macrophage-
derived chemokine [MDC], macrophage inflammatory
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protein [MIP]-1α, MIP-1β and thymus- and activation-
regulated chemokine [TARC]) (data not shown).
The neo-angiogenic potential of humanMAPCs was tested
using the CAM angiogenesis model. Inoculation with 5 μg
recombinant human VEGF markedly increased the number of
blood vessels directed toward the implant (Fig. 1c). Human
MAPCs (2.5×105) significantly increased vessel formation
by 2.5- and 4.6-fold compared with control implants
containing either 150 C57BL/6 mouse islets or 50 μg BSA,
respectively (Fig. 1c).
Co-transplantation of islets–human MAPCs as a compo-
site pellet improves the outcome of marginal mass islet
transplantation We titrated the number of pancreatic islets
transplanted to determine ‘a marginal islet mass’ that would
be just at the edge of achieving normoglycaemia in around
50% of recipients. Transplantation of 50 syngeneic C57BL/6
islets did not reverse hyperglycaemia (0 out of 7 mice), where-
as 100% (4 out of 4 mice) achieved normoglycaemia when
300 islets were transplanted under the kidney capsule. We
assessed that the marginal islet number was approximately
150 islets (25 out of 45 mice, 56% achieving normal blood
glucose concentrations 5 weeks post-transplantation). This
number of islets was selected for further experiments.
Next, we investigated the outcome of the co-transplanted
marginal islet mass with 2.5×105 human MAPCs as separate
or composite pellets and monitored the blood glucose levels of
transplanted mice for up to 5 weeks. Co-transplantation of
pancreatic islets with human MAPCs as separate pellets
(SEP) slightly improved the average blood glucose concentra-
tions compared with mice transplanted with islets alone.
Interestingly, mice receiving islet–human MAPC composites
(MIX) had better glycaemic control at all measured time
points from 2 weeks onwards (Fig. 2a). Three weeks after
transplantation, 81% of the MIX mice (13 out of 16 mice)
were normoglycaemic compared with 50% of the SEP mice
(13 out of 26 mice; p<0.05) and 47% in the mice transplanted
with islets alone (21 out of 45 mice in the control group;
p<0.05) (Fig. 2b). By the end of the observation period (week
5 post-transplantation), an even greater proportion of mice co-
transplanted with islets–human MAPCs reversed diabetes
compared with mice transplanted with islets alone (94% in
the MIX group [p < 0.01] and 85% in the SEP group
[p<0.001] vs 56% in the control group). After nephrectomy,
the blood glucose concentrations of normoglycaemic islet
recipients rapidly progressed to severe hyperglycaemia, indi-
cating that the improvement in metabolic glucose control had
resulted from the transplanted syngeneic islets and not from
the regeneration of remnant islets in the alloxan-treated
pancreas of the islet recipients (ESM Fig. 1 a–c). Moreover,
there was no significant difference in body weight between
transplant recipients from different experimental groups on
day 0 (22.8± 0.27 g, 23.5 ± 0.2 g and 22.9±0.21 g for the
control, SEP and MIX groups, respectively; n=40–52) or at
week 5 post-transplantation (25.6±0.33 g, 26.2±0.32 g and
25.4 ± 0.27 g, for the control, SEP and MIX groups,
respectively; n=40–52) (ESM Fig. 1d).
Serum insulin and C-peptide levels were measured at 2 and
5 weeks after transplantation, as an index of islet graft func-
tion. At week 2 post-transplantation, insulin and C-peptide
concentrations did not differ significantly between the various
experimental groups (ESM Fig. 2 a, b). However, at week 5
post-transplantation, C-peptide values were significantly
higher in the SEP mice (304±80 pmol/l; n=10, p<0.01) as
well as in the MIX mice (282±77 pmol/l in the MIX group;
n=10, p=0.05) when compared with values from the mice
transplanted with islets alone (232±52 pmol/l in the control
group; n=10) (ESM Fig. 2 c, d).
To investigate the insulin secretory capacity of the islet
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Fig. 1 Characterisation of human MAPCs. (a) Cell surface marker ex-
pression of human bone marrow-derived MAPCs. Flow cytometry histo-
grams show the expression levels (peaks shaded dark grey) of selected
markers associated with the characterisation of human MAPCs (CD44
and CD105) compared with negative isotype controls (peaks shaded light
grey). (b) Culture medium of human MAPCs was analysed with human
biomarker 40-Plex kit containing a pro-inflammatory panel, cytokine
panel, chemokine panel, angiogenesis panel and vascular inflammation
panel. Data are means ± SEM. SAA, serum amyloid A; sVCAM-1, solu-
ble vascular cell adhesion molecule-1; CRP, C-reactive protein. (c) Pro-
angiogenic properties of 2.5 × 105 human MAPCs (hMAPC) with or
without 150 C57BL/6mouse islets in a CAM assay; 150 C57BL/6mouse
islets alone and BSA were used as negative controls and VEGF-A as
positive control (mean ± SEM, n = 3–9 per group). **p < 0.01 and
***p< 0.001 for indicated comparisons
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and 5 post-transplantation. At week 2 post-transplantation,
there were no significant differences in glucose clearance among
the studied groups (Fig. 2 c, d). At week 5 post-transplantation,
however, MIX mice cleared glucose more efficiently than SEP
mice or mice transplanted with islets alone (control) (Fig. 2 e, f).
To further support the observations from the IPGTT, the AUC
was calculated and found to differ significantly between the
MIX group and the SEP group (p < 0.01) or the group
transplanted with islets alone (control) (p<0.01). (Fig. 2e).
Increased beta and alpha cell volume and blood vessel
formation in mice transplanted with islet–human MAPC
composites Grafts from the three groups of mice were
evaluated for their gene profile, cytoarchitecture and
revascularisation process. Insulin and glucagon mRNA
expression levels were significantly higher in MIX mice than
in the mice transplanted with islets alone (control) 2 weeks
after transplantation (Fig. 3 a, b). There was no difference in
somatostatin mRNA expression levels at this time point
(Fig. 3c). At week 5 post-transplantation, the intra-graft
mRNA levels of the studied endocrine hormones were similar
in all groups. These measures were corroborated by
histological analysis of the grafts, which showed significantly
higher insulin-, glucagon- and somatostatin-positive areas in
the grafts of MIX mice 2 weeks after transplantation when
compared with grafts from mice transplanted with islets only
(control) (Fig. 3 d–g).
The formation of blood vessels was assessed by measuring
the expression of endomucin, a marker for vascular endothe-
lial cells. At week 2 post-transplantation, graft vessel density
and area, as well as the ratio of the vessel area to insulin-
positive area, did not differ between the studied groups (data
not shown). At week 5 post-transplantation, enhanced graft
revascularisation was observed in MIX mice compared with
SEP mice or mice transplanted with islets alone (control)
(Fig. 4a). In the MIX grafts, 1256±203 vessels/mm2 were
detected compared with 702 ± 106/mm2 in the SEP grafts
and 515± 52/mm2 in the islet-alone grafts (both p< 0.05;
Fig. 4b). Another index of neo-angiogenesis, graft vessel area,
was significantly higher in the MIX grafts (4.85 ± 1.32%,
n=5) than in the grafts of islets only (1.26±0.25%; n=4,
p<0.05, Fig. 4c). Additionally, mice transplanted with the
MIX grafts had a higher ratio of vessel per insulin-positive
area than either the SEP grafts or the islet-alone grafts (0.079
±0.027 vs 0.019±0.006 and 0.014±0.003 vessels per islet,
both p<0.01) (Fig. 4d). Collectively, grafts composed of islets
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Fig. 2 In vivo function of a marginal islet mass co-transplanted with
human MAPCs. (a) Blood glucose measurements of alloxan-induced
diabetic C57BL/6 mice transplanted with 150 islets alone (control
[n = 47]; white bars) or with 150 islets co-transplanted as separate
(n = 52; dark-grey bars) or composite pellets (n = 40; light-grey bars) with
2.5 × 105 human MAPCs. Floating bars extend from the minimum to the
maximum, the line indicates the mean.*p < 0.05, **p < 0.01 and
***p< 0.001 vs islets alone (control). (b) Percentage of cured (black bars)
and non-cured (grey bars) mice after islet transplantation. (c–f) AUCs and
blood glucose measurements after IPGTTs in mice transplanted with a
marginal islet mass alone (control, white circles) or combined with human
MAPCs as a separate (crossed circles) or composite pellet (grey circles) 2
(c, d) and 5 (e, f) weeks after transplantation. **p< 0.01 for indicated
comparisons. The box extends from the 25th to 75th percentiles, the line
indicates the median, and the Tukeymethodwas used to plot the whiskers
and the outliers (solid black dots); (d, f) mean ± SEM
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mixed with human MAPCs retrieved 5 weeks after transplan-
tation contained high numbers of endomucin-positive
endothelial cells (Fig. 4a) and only a few α-SMA-positive
cells (ESM Fig. 3a), indicating the presence of new
capillary-like structures. Moreover, PCR analyses demonstra-
ted that both mouse Cd31 (Pecam1) and mouse α-SMA
(Acta2) mRNA were more abundantly present in the MIX
grafts than in the grafts of islets alone (ESM Fig. 3 b, c), while
expression of the basement membrane marker Col4a1 did not
differ among the experimental groups (data not shown).
Discussion
Several hurdles still prevent the progression of clinical islet
transplantation, including early graft failure and the loss of
transplanted islet mass due to non-immunological reasons
[28]. In the first days following transplantation, islets lack an
adequate vascular network, leading to severe hypoxia and cell
death. It is believed that this is one of the major causes for the
poor performance of islet grafts long-term. Therefore, there is
a need of methods to improve the early survival, function and
engraftment of transplanted islets. A variety of (stem) cell
populations (i.e. endothelial progenitor cells, MSCs) have
been described for enhancing transplanted beta cell survival
and function after co-transplantation; however, there are still a
number of problems relating to their wide-scale application in
the clinic, such as inconsistent stem cell potency, poor cell
engraftment and survival and age/disease-related host tissue
impairment [29].
MAPCs are a novel class of progenitor cells and can be
derived from the postnatal bone marrow stroma compartment
and also from muscle and brain of several species, including
rodents and humans [13]. These cells have demonstrated
extensive in vitro expansion capacity, durable cytogenetic
stability and higher plasticity when compared with MSCs
[30]. MAPCs are also non-immunogenic and have a strong



















































































































































































































































































































Fig. 3 Morphology and composition of islets co-transplanted with hu-
man MAPCs examined at 2 and 5 weeks post-transplantation. (a–c) Box
and whiskers plots of mRNA levels of mouse insulin, glucagon and
somatostatin in isolated islet grafts derived from mice transplanted with
a marginal islet mass alone (control) or combined with humanMAPCs as
a separate or composite pellet. Values were normalised to the geometric
mean of housekeeping genes. Data are expressed as 2−ΔΔCt . The box
extends from the 25th to 75th percentiles, the line indicates the median,
and the Tukey method was used to plot the whiskers and the outliers.
Statistical significance was calculated using Mann–Whitney t tests.
*p < 0.05 for indicated comparisons. (d–f) Box and whiskers plots of
volumes of beta, alpha and delta cells of grafts derived from mice
transplanted with a marginal islet mass alone or combined with human
MAPCs as a separate or composite pellet. The box extends from the 25th
to 75th percentiles, the line indicates the median, and the Tukey method
was used to plot the whiskers and the outliers. Statistical significance was
calculated using Mann–Whitney t tests. *p< 0.05 and **p < 0.01 for in-
dicated comparisons. (g) Distribution of mouse insulin- (white), gluca-
gon- (red), and somatostatin (green)-positive cells in islet grafts com-
posed of islets and human MAPCs as separate (SEP) or composite
(MIX) pellets or of islets alone (control) at 2 weeks post-transplantation.
Stitched composite images are representative of sections from 4–8 differ-
ent mice. Scale bar, 100 μm. Higher magnification of the boxed area in
control demonstrates a compact graft with normal distribution of insulin,
glucagon and somatostatin positivity. Higher magnification of the boxed
area in the SEP andMIX groups shows spread-out grafts with high insulin
and glucagon positivity
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non-HLA-matched allogeneic and even xenogeneic use
without the need for immunosuppression [36, 37].
Interestingly, MAPCs seemed to exhibit an unusual capacity
to evade the immune system and can regulate homeostatic T
cell proliferation, prevent the expansion of T helper (Th) 1,
Th17 and Th22 effector T cells and block the development of
pathogenic allogeneic responses [31]. Moreover, MAPCs
have been reported to secrete angiogenic growth factors and
to improve vascular remodelling in different models of
ischaemia, such as those for cardiac infarction and severe limb
ischaemia [20, 37]. Based on these phenotypic and functional
characteristics, we wanted to study the localised effect of
human MAPCs on islet graft function in a murine syngeneic
marginal mass transplant model.
Here we show for the first time that human MAPCs
co-transplanted as composite pellets with mouse islets can
improve islet graft function as measured by the initial
glycaemic control, diabetes reversal rate, glucose tolerance
and serum C-peptide concentration when compared with
transplantation of islets alone. Moreover, we found that grafts
composed of islet–human MAPC composites had an
improved revascularisation process. The human MAPCs
actively participated in the revascularisation process mainly
by producing angiogenic growth factors, soluble adhesion
molecules and IL8.
Several studies have shown that MAPCs from both
allogeneic and xenogeneic sources exert positive effects
in models of ischaemia, mainly through the secretion of
trophic factors such as VEGF-A, platelet-derived growth
factor and IGF-1 [37, 38]. Our present data corroborated
the angiogenic potency of human MAPCs, as superna-
tant fractions of cultured cells were shown to contain
high concentrations of vascular inflammation and angio-
genic factors such as VEGF-A, PlGF and bFGF, all
major regula tors of is le t vascular i sa t ion . The
neo-angiogenic potential of human MAPCs was further
validated in vivo in a chicken CAM assay, where
implanted human MAPCs formed new blood vessels at
a rate comparable with that observed with recombinant
VEGF-A. VEGF-A is considered to be one of the major
regulators of islet vascularisation, innervation and func-
tion, as beta cell-specific deletion of VEGF-A leads to
diminished and abnormal islet vascularity, impaired
postnatal nerve fibre ingrowth and dysregulated
glucose-stimulated insulin secretion [39–41]. Moreover,
VEGF-A seems to be required for revascularisation of
transplanted islets. Based on these data, several investi-
gators have tried to enhance VEGF production locally
in the pancreatic islets, although not continuously as
this might trigger vascular tumour formation [42–44].
It has been reported that islets co-transplanted with
human embryonic stem cell-derived MSCs that
conditionally overexpress VEGF allow a 50% reduction
in the islet mass required to reverse diabetes in mice.
These cells significantly improved islet metabolic

















































































































Fig. 4 Co-transplantation of islets with human MAPCs as composites
promotes graft revascularisation in a marginal islet mass diabetic mouse
model. (a) Representative sections of 5 week grafts consisting of mouse
islets transplanted alone (control) or with human MAPCs as separate or
composite pellets. Images are representative of insulin and endomucin
(vessel) staining for 3 or 4 mice in each transplant group. Scale bar,
100 μm. (b–d) Assessment of vessel morphological variables was carried
out as described in the Methods. Data are means ± SEM. Statistical anal-
ysis was performed using Mann–Whitney t tests. *p < 0.05 and
**p< 0.01 for indicated comparisons
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Islet engraftment is a slow process, and while vascular
sprouting, angiogenesis and revascularisation occur within
1–2 weeks after transplantation, the maturation of the
blood vessels is likely to take several weeks to even
months. Although VEGF can boost the process of islet
revascularisation, this protein is also critical for
maintenance of the intra-islet endothelial cell pool [40].
We found a significant improvement in the development
of a new islet capillary network in mice where islets were
co-transplanted with islet–human MAPCs. Indeed, higher
numbers of capillary-like structures with a lining of
endothelial cells (detected with mouse-specific endomucin
antibody) were found on the periphery and in the intra-islet
space of the islet–human MAPC composites at week 5
post-transplantation. This suggests that host-derived
vessels are directly feeding transplanted islets and that
close proximity and even direct contact between the
transplanted pancreatic islets and human MAPCs is of
critical importance for the improved glucose control,
diabetes reversal rate and increased revascularisation.
Absence of human Cd31 (Pecam1) mRNA expression in
the islet grafts further supports the idea that human MAPCs
are not incorporated into new capillaries but possibly
secrete growth factors to initiate angiogenesis and to
support functional tissue survival (data not shown). These
observations are in full agreement with previous observa-
tions that the major role of human MAPCs is to provide
angiogenic growth factors in the first days after implanta-
tion, after which they are cleared rapidly from the body,
without leading to immune activation [18, 37].
The present data encouraged the use of human MAPCs in
islet transplantation protocols as our results demonstrate the
improvement of islet graft morphology and function by
transplantation of islet–human MAPC composites, possibly
via the promotion of graft revascularisation mediated by
human MAPCs.
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